RecruitingAgitation Associated With Alzheimer's Disease Dementia
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Eligible age
55–90 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Sponsor: Exciva GmbH
You may qualify if…
- ✓ 1. The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair.
- ✓ 2. A previously established diagnosis of AD dementia.
- ✓ 3. The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
- ✓ 4. The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
- ✓ 5. Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day.
You may not qualify if…
- ✕ 1. The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia.
- ✕ 2. The participant has symptoms of agitation that are not secondary to AD dementia
- ✕ 3. The participant has a history of uncontrolled seizures or a history of epilepsy.
- ✕ 4. The participant has a major medical illness or unstable medical condition
Where it's recruiting
California
Murrieta
Indiana
Indianapolis
Mississippi
Flowood
Missouri
Chesterfield
New York
Brooklyn · New York
Ohio
Independence
Oregon
Portland
Vermont
Bennington
Source: ClinicalTrials.gov · NCT07284472 · last updated 2026-06-05